Compare · PTHS vs SGEN
PTHS vs SGEN
Side-by-side comparison of Pelthos Therapeutics Inc. (PTHS) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PTHS and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 248.8x PTHS ($93.8M).
- PTHS has hit the wire 5 times in the past 4 weeks while SGEN has been quiet.
- SGEN has more recent analyst coverage (25 ratings vs 6 for PTHS).
- Company
- Pelthos Therapeutics Inc.
- Seagen Inc.
- Price
- -
- -
- Market cap
- $93.8M
- $23.34B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
- NASDAQ
- IPO
- 2024
- 2001
- News (4w)
- 5
- 0
- Recent ratings
- 6
- 25
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest PTHS
- Director Friedberg Ezra M sold $14,556 worth of shares (558 units at $26.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 81,042 units (SEC Form 4) to cover withholding tax
- Director Pauls Matthew sold $20,561 worth of shares (786 units at $26.16) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 14,364 units (SEC Form 4) to satisfy withholding tax
- Director Greenleaf Peter sold $20,827 worth of shares (797 units at $26.13) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 23,884 units (SEC Form 4) to satisfy withholding tax
- Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- Director Friedberg Ezra M sold $7,724 worth of shares (283 units at $27.29) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 81,600 units (SEC Form 4) to satisfy tax liability
- Director Davis Todd C bought $999,983 worth of shares (35,948 units at $27.82), increasing direct ownership by 90% to 75,834 units (SEC Form 4)
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
- CFO, Treas & Secty Francis Knuettel Ii returned 13,947 shares to the company and sold $40,265 worth of shares (1,500 units at $26.84), decreasing direct ownership by 42% to 19,525 units (SEC Form 4)
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)